Article Details
Retrieved on: 2024-05-15 15:08:16
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the rapid growth of the RNAi therapeutics market, which is anticipated to expand significantly due to its effective gene-silencing capabilities, primarily in treating cancers and other genetic diseases. Biopharma companies like Alnylam Pharmaceuticals are frontrunners in leveraging RNAi technologies.
Article found on: www.investorsobserver.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here